Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Texas Biotech negotiating with Genentech to keep argatroban license; NDA deadline will not be met.

Executive Summary

TEXAS BIOTECH RENEGOTIATING ARGATROBAN LICENSING WITH GENENTECH: the agreement as it now stands returns rights for Novastan (argatroban) to Genentech if Texas Biotechnology does not file an NDA by June 30 unless "there is good cause to delay such filing." The NDA will not be filed this year. The agreement, signed in May 1993, covers Canada and the U.S. Genentech licensed the antithrombolytic agent argatroban from Mitsubishi, which manufactures the drug for TBC.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026430

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel